A new targeted therapy for metastatic castration-resistant prostate cancer (mCRPC), Akeega®, is already funded and available in Spain after approval of pricing and reimbursement by the National Healthcare System. This step constitutes a significant advance in the approach to this pathology and highlights the key role of molecular diagnosis in clinical practice.
January 26, 2026.
A fixed-dose combination of niraparib, a PARP inhibitor, and abiraterone acetate, “it is indicated for adult mCRPC patients with both germline and somatic alterations in the BRCA1/2 genes in whom chemotherapy is not clinically appropriate or is delayed. Its effective integration into healthcare practice strengthens the use of biomarker-based targeted therapies for this type of cancer”, said Inés Calabria, PhD, Head of the Oncology Clinical Area at Health in Code.
Its approval is based on the results of the MAGNITUDE phase III study, which showed a 47% decrease in the risk of radiological progression or death, as well as a longer control of the disease in patients with BRCA1/2 mutations.
Molecular diagnosis, at the center of therapeutic decision-making
This novel therapeutic scenario reiterates the position of new-generation sequencing (NGS) as an indispensable tool for the management of advanced prostate cancer. The accurate identification of alterations in BRCA1/2 becomes a key step for the early selection of candidate patients for targeted therapy.
Within this context, at Health in Code, a company specializing in genetic diagnosis, we highlight the need for NGS panels able to test large genes such as BRCA1 and BRCA2 with a high reliability, coverage, and speed, overcoming the current limitations of panels that do not include these genes.
Health in Code’s Action OncoKit NGS panel allows for their study by probe capture and sequencing by synthesis of actionable genes within the context of adult solid tumors. “This molecular test can be requested at our laboratory by submitting the patient’s tumor sample, and the report can be received within a 10-day period. A testing kit can also be requested to carry out the test in your own facilities, providing all the necessary technical and clinical support for its correct performance”, stated Marcia Ajenjo, Business Oncology Manager at Health in Code.
A solidifying trend
The approval of Akeega® is not an isolated event. The recent authorization of other treatments targeting mutations in BRCA1/2, such as talazoparib (Talzenna®), confirms a clear trend: precision medicine is already a part of the standard of care in metastatic prostate cancer.
In this new scenario, comprehensive molecular diagnosis of both somatic and germline alterations is established as an essential component of informed and personalized therapeutic decision-making.
